PrimeRFP SCOUT · Federal Contract Profile

Glaxosmithkline (FRHTPHMZMX47)Federal contracts · 11 recompetes

Glaxosmithkline holds $2.97B in federal volume across 194 award actions, with 100% at Department of Health and Human Services (HHS). SCOUT tracks 11 incumbent recompetes — an estimated $265.1M returning to market over the next 24 months (High exposure). Primary work: Pharmaceutical Preparation; Biological Product Manufacturing (95% prime). Obligations are down 16% year over year.

$2.97B

Federal Volume

Recompetes (24mo)

HHS

Top Agency · 100% firm-wide

194

Award Actions

Choose one — this changes what we ask next

Score my firm against Glaxosmithkline

Email me when a Glaxosmithkline recompete window opens.

Data through August 2026 · refreshed monthly · window Aug 2025 – Aug 2026

What they do

Capability

Service lines

PHARMACEUTICAL PREPARATION MANUFACTURING · BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

Work mix: 95% prime · 5% sub · primary NAICS 325412 / PSC 6505 DRUGS AND BIOLOGICALS

Where they win

5 agencies

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%

Department of Defense (DOD)$1.7M · 0%

Department of Veterans Affairs (VA)$1.5M · 0%

Department of State (DOS)$1.2M · 0%

Department of Justice (DOJ)$772K · 0%

Recompete exposure: High · 11 in 24mo

Glaxosmithkline has an estimated $265.1M in contracts returning to market over the next 24 months.

Who buys from them

Agency buyer map

5 buyers

Department of Health and Human Services (HHS)217 awards · repeat buyer · $3.0B

Department of Defense (DOD)10 awards · repeat buyer · $1.7M

Department of Veterans Affairs (VA)108 awards · repeat buyer · $1.5M

Department of State (DOS)6 awards · repeat buyer · $1.2M

Department of Justice (DOJ)87 awards · repeat buyer · $772K

Recompete exposure & trajectory

Recompete exposure

High

Glaxosmithkline has an estimated $265.1M in contracts returning to market over the next 24 months. 4 within 6 months ($1.2M).

FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E →

PIID: 75A50125F61019 · Expires 2026-08-30

$491K

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE S →

PIID: 75A50126F61020 · Expires 2026-10-29

$493K

GSK TRAVEL VACCINES →

PIID: 15F06724F0001366 · Expires 2026-12-31

$115K

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187 →

PIID: 15F06726F0000234 · Expires 2026-12-31

$105K

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL COUNTERMEASURES (MCMS) FOR PANDEMIC INFLUENZA AND →

PIID: 75A50124F61014 · Expires 2027-02-21

$18.4M

THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) TO SUPPORT THE COVID-19 FEDERAL RESPONSE- MULTI-DO →

PIID: 75A50124F61013 · Expires 2027-02-21

$15.4M

THE PURPOSE OF THIS TASK ORDER IS TO PROCURE STORAGE AND STABILITY FOR ANTIGENS AND ADJUVANTS FROM PRIOR CONTRACTS FOR THE DEPARTMENT OF HEA →

PIID: 75A50124F61010 · Expires 2027-05-21

$40.9M

THE PURPOSE OF THIS HHS TASK ORDER IS TO PROCURE SERVICES FOR THE STORAGE AND STABILITY OF BULK LOTS & FINAL CONTAINERS OF-ADJUVANT( AS03) C →

PIID: 75A50124F61012 · Expires 2027-05-21

$14.0M

THE PURPOSE OF THIS TASK ORDER IS TO REQUEST THE FILL/FINISH OF ONE (1) CGMP ADJUVANT BULK LOT UNDER CLIN 0006E. FILL/FINISH AND RELEASE AS →

PIID: 75A50124F61009 · Expires 2027-05-21

$2.3M

THE PURPOSE OF THIS TASK ORDER IS TO PROCURE SERVICES FOR STORAGE AND STABILITY VACCINE BULK LOTS FROM PRIOR CONTRACTS FOR U.S. DEPARTMENT O →

PIID: 75A50124F61011 · Expires 2027-05-21

$1.1M

PURPOSE OF THIS MODIFICATION IS TO: 1. ACCEPT TRANSFER ACCOUNTABILITY OF 5,015,690 VIALS (50.1 MILLION DOSES) OF AS03 ADJUVANT FROM CONTRAC →

PIID: 75A50123F61005 · Expires 2027-12-31

$171.6M

Trajectory

▼ Consolidating-16% YoYFY2025 vs FY2024

'23

'24

'25

Teaming relationships

Glaxosmithkline teams with

ASD SPECIALTY HEALTHCARE, LLCas prime with

TEXAS A&M UNIVERSITY SYSTEM,THEas sub to

TRUSTEES OF BOSTON UNIVERSITY →as sub to

MESO SCALE DIAGNOSTICS, LLC →as sub to

UNIVERSITY OF SOUTHERN CALIFORNIA →as sub to

Partners from federal subaward / teaming records (public).

“With competitive federal procurements, winning starts with strategically understanding the customer environment to the left of SAM.gov. This is what SCOUT does - a deeper and more precise understanding of what the…”

— Peter Lierni, Solutioneering

Explore another company

Don’t see your company?

Enter your company name and we'll build the page.

Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →

Frequently asked questions

What federal contracts does Glaxosmithkline hold?

Glaxosmithkline (UEI FRHTPHMZMX47) shows $3.0B across 194 award actions in SCOUT’s public USASpending-backed profile, with Department of Health and Human Services (HHS) as the top buying agency. Totals cover federal prime awards ≥$100K in the rolling window.

How much in federal contracts does Glaxosmithkline have?

Glaxosmithkline shows $3.0B across 194 award actions. SCOUT tracks 11 incumbent recompetes ($265.1M) returning to market in the next 24 months.

Which agencies does Glaxosmithkline work with?

Glaxosmithkline’s firm-wide obligated mix is led by Department of Health and Human Services (HHS) (100%), Department of Defense (DOD) (0%), Department of Veterans Affairs (VA) (0%).

What is the UEI for Glaxosmithkline?

The Unique Entity ID (UEI) for Glaxosmithkline is FRHTPHMZMX47.

Does Glaxosmithkline have contracts coming up for recompete?

Yes — SCOUT tracks 11 incumbent recompetes in the next 24 months (High exposure). Open the recompete section on this page for PIID-level timing.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.